Especially, Ferguson and Nabet48 discovered DCLK1‐IN‐1, a selective inhibitor of DCLK1, and demonstrated the activity of DCLK1‐IN‐1 against clinically relevant patient‐derived pancreatic ductal carcinoma organoid models. The gene discussed is DCLK1; the disease is pancreatic ductal adenocarcinoma.